Premium
Hematopoietic effects of a folate antagonist in man
Author(s) -
Speck Bruno,
Kiely Joseph M.,
Pease Gertrude L.
Publication year - 1967
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1967)20:2<225::aid-cncr2820200208>3.0.co;2-6
Subject(s) - medicine , granulopoiesis , erythropoiesis , methotrexate , folic acid antagonists , antagonist , haematopoiesis , bone marrow , pharmacology , anemia , receptor , genetics , stem cell , biology
In hematologically normal patients with cancer, a folate antagonist (methotrexate) decreased erythropoiesis quantitatively as well as qualitatively. Granulopoiesis also was reduced but the changes were not as great. One month after drug therapy was discontinued the marrow and peripheral blood returned essentially to normal.